Is SNTA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

774 people get SNTA articles and Market Currents by email alert.

Get email alerts on SNTA »

HEADLINES:

Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting

Business Wire (Wed, 6:30PM)
Synta Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Synta Provides Clinical Updates and Reports First Quarter 2013 Financial Results

Business Wire (Apr 30, 2013)
Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer

Business Wire (Apr 22, 2013)
Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013

Business Wire (Apr 16, 2013)
Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research

Business Wire (Apr 5, 2013)
Synta's Slump On Shelf Registration Provides Entry Point Ahead Of ASCO
PropThink • Mon, Mar 25
Synta Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 14
Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results

Business Wire (Mar 14, 2013)
Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development

Business Wire (Mar 13, 2013)
Synta Pharmaceuticals' Management Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
Trius Therapeutics: New MRSA Treatment Could Bring Billions In Revenues
Scott Matusow • Tue, Mar 5 • 8 Comments
Synta Pharmaceuticals' Subgroup Selection Strategy Is A Set-Up For Success
PropThink • Thu, Feb 28 • 6 Comments
Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013

Business Wire (Feb 25, 2013)
Synta to Present at Upcoming Conferences

Business Wire (Feb 11, 2013)
VIX - Options Volatility And Market Sonar: Tuesday Recap
Erick McKitterick • Tue, Feb 5 • 5 Comments
Insiders Love These 3 Highly Shorted Healthcare Stocks
Kapitall • Wed, Jan 23 • 1 Comment
Synta: Share Price Not Reflecting Ganetespib Value Proposition
Poonam A. Arora • Tue, Jan 15 • 6 Comments
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments

To learn more about Seeking Alpha Pro, click here.

Synta's Slump On Shelf Registration Provides Entry Point Ahead Of ASCO
PropThink • Mon, Mar 25
Synta Pharmaceuticals' Subgroup Selection Strategy Is A Set-Up For Success
PropThink • Thu, Feb 28 • 6 Comments
Synta: Share Price Not Reflecting Ganetespib Value Proposition
Poonam A. Arora • Tue, Jan 15 • 6 Comments
Synta Pharma: Poised For A Breakout With 4 Near-Term Catalysts
Scott Matusow • Thu, Dec 13, 2012 • 5 Comments
Synta - The Signal Looks Real
Ohad Hammer • Tue, Jul 10, 2012 • 5 Comments
3 Reasons To Buy Synta Pharmaceuticals
Markus Aarnio • Mon, Jul 2, 2012 • 7 Comments
Synta Pharmaceuticals Has Long-Term Potential
Roy Manning III • Thu, May 10, 2012 • 5 Comments
Synta Readying 2 Key Lung Cancer Trials
Len Zehr • Wed, Apr 20, 2011
Putting a Price Tag on Synta's Lead Drug Activities
Ohad Hammer • Sun, Mar 20, 2011
Synta's Lead Program Gains Momentum
Ohad Hammer • Sun, Dec 5, 2010 • 4 Comments
Will Synta Break A 30-Year Old Record? (Part II)
Ohad Hammer • Wed, Apr 30, 2008 • 2 Comments
Will Synta Pharmaceuticals Break A 30 Year Old Record?
Ohad Hammer • Mon, Apr 21, 2008 • 1 Comment
Evaluating Synta Pharmaceuticals' Cashflow
Brian Orelli • Mon, Mar 26, 2007
Recent IPO Synta Pharma Sees Strong Insider Buying
Richard Shonfeld • Tue, Feb 27, 2007

George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
Trius Therapeutics: New MRSA Treatment Could Bring Billions In Revenues
Scott Matusow • Tue, Mar 5 • 8 Comments
VIX - Options Volatility And Market Sonar: Tuesday Recap
Erick McKitterick • Tue, Feb 5 • 5 Comments
Insiders Love These 3 Highly Shorted Healthcare Stocks
Kapitall • Wed, Jan 23 • 1 Comment
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments
Tuesday's Small-Cap Biopharma Catalyst Trade List
Scott Matusow • Tue, Dec 11, 2012 • 19 Comments
17 Stocks In The Battle Zone -- Insiders Vs. Short Sellers
John Connors • Tue, Dec 11, 2012 • 7 Comments
8 Highly Shorted Stocks Insiders Are Buying
Kapitall • Tue, Nov 20, 2012 • 5 Comments
What Is So Exciting About MEI Pharma?
C.R. Jackson • Fri, Nov 16, 2012 • 2 Comments
5 Healthcare Companies With Significant Recent Insider Buying (Part IV)
Markus Aarnio • Wed, Nov 14, 2012
Investments In The Fight Against Cancer: The Analysts' Choices
Glen S. Woods • Mon, Nov 5, 2012
Winners Of ESMO 2012
Ohad Hammer • Mon, Oct 8, 2012 • 6 Comments
Weekend Recap: Biotech Madness
Brian L. Wilson • Sat, Oct 6, 2012 • 14 Comments
Ariad Pharmaceuticals' AP26113: Strong Data For ALK+ Lung Cancer
Longwood Bulls • Tue, Oct 2, 2012 • 3 Comments
2.4% Yield And 10+ Potential Blockbuster Drugs
The Wall Street Transcript • Wed, Sep 26, 2012 • 15 Comments
5 Highly Shorted Small-Caps With Strong Insider And Institutional Buying
Kapitall • Tue, Sep 18, 2012
QE3, ECB Or Bust
David Brown • Wed, Aug 1, 2012 • 2 Comments
Cancer Vaccines Show Positive Results For Both Patients And Investors
Henry Kawabe • Tue, Jul 24, 2012 • 2 Comments
A Collar On Steroids - The Covered Call Ratio Spread
William Campbell • Fri, Jul 13, 2012 • 7 Comments
Insiders Love These 10 Outperforming Healthcare Stocks
Kapitall • Tue, Jul 10, 2012

Synta Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Synta Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 14
Synta Pharmaceuticals' Management Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
Synta Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 6, 2012
Synta Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
Synta Pharmaceuticals Corp. Q1 2010 Earnings Call Transcript
Tue, May 4, 2010
Synta Pharmaceuticals Corp. Q3 2009 Earnings Call Transcript
Wed, Nov 4, 2009
Synta Pharmaceuticals Corp. Q3 2008 Earnings Call Transcript
Thu, Nov 13, 2008
Synta Pharmaceuticals Corp. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Synta Pharmaceuticals Corp. Q1 2008 Earnings Call Transcript
Tue, May 27, 2008
Synta Pharmaceuticals Corp. Q4 2007 Earnings Call Transcript
Thu, Mar 20, 2008

Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting

Business Wire (Wed, 6:30PM)
Synta Provides Clinical Updates and Reports First Quarter 2013 Financial Results

Business Wire (Apr 30, 2013)
Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer

Business Wire (Apr 22, 2013)
Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013

Business Wire (Apr 16, 2013)
Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research

Business Wire (Apr 5, 2013)
Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results

Business Wire (Mar 14, 2013)
Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development

Business Wire (Mar 13, 2013)
Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013

Business Wire (Feb 25, 2013)
Synta to Present at Upcoming Conferences

Business Wire (Feb 11, 2013)
Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering

Business Wire (Dec 13, 2012)
Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock

Business Wire (Dec 12, 2012)
Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST

Business Wire (Nov 27, 2012)
Interim Results of the Phase 2b/3 GALAXY Trial to be Presented at the Fifth Asia Pacific Lung Cancer Conference

Business Wire (Nov 26, 2012)
Synta to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Business Wire (Nov 9, 2012)
Interim Results of the Phase 2b GALAXY Trial to be Presented at the Chemotherapy Foundation Symposium

Business Wire (Nov 7, 2012)
Synta Provides Clinical Update and Reports Third Quarter 2012 Financial Results

Business Wire (Nov 6, 2012)
Synta to Host Third Quarter 2012 Conference Call on November 6, 2012

Business Wire (Oct 24, 2012)
Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer

Business Wire (Oct 1, 2012)
Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer

Business Wire (Sep 29, 2012)
Synta to Present Interim Results from the GALAXY™ Trial at ESMO 2012

Business Wire (Sep 18, 2012)

SNTA vs. ETF Alternatives

Company Description

Currently, there's no company description for SNTA.

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 12:53 PM Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move]
Tuesday, May 7, 12:52 PM Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%. Comment! [On the Move]
Tuesday, April 30, 6:57 AM Synta Pharmaceuticals (SNTA): Q1 EPS of -$0.30 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 14, 8:00 AM Synta Pharmaceuticals (SNTA): Q4 EPS of -$0.29 misses by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, December 13, 2012, 12:24 PM Synta Pharmaceuticals (SNTA +3.6%) trades up after saying it's entered into stock purchase agreements with members of its Board and various institutional investors to sell 7M shares of its common stock in an issuer directed, registered direct offering. Shares were priced at $8.60, yesterday's closing bid price. Gross proceeds from the sale were approximately $60M. Comment! [Healthcare, On the Move]
Monday, November 12, 2012, 5:45 PM After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%.
After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER -4.4%. GME -4.1%. MWE -3.7%. Comment! [On the Move]
Monday, October 1, 2012, 12:45 PM Midday top 10 gainers: CRDN +43%. FONR +34%. BIOF +19%. VSR +17%. MTG +16%. SNTA +16%. VSNT +15%. PATK +14%. MGI +12%. SFUN +12%.
Top 10 Losers: NC -65%. TYC -49%. GMAN -24%. BYFC -17%. THLD -17%. PPHM -16%. GNI -11%. OCZ -10%. ROSG -10%. CYTX -8%. 1 Comment [On the Move]
Monday, October 1, 2012, 10:39 AM Synta Pharmaceuticals (SNTA +11.6%) pops after reporting encouraging results from its Phase 2b Galaxy trial of ganetespib - the company's lead Hsp90 inhibitor - as second-line treatment for advanced non-small cell lung cancer. The company says test results showed good tolerability for the combination of ganetespib and docetaxel as well as meaningful improvements in overall survival in adenocarcinoma patients receiving the drug combination. Comment! [Healthcare, On the Move]
Thursday, June 28, 2012, 12:10 PM Synta Pharmaceuticals (SNTA) -30% and extending its losses from AH trading yesterday after disclosing mixed interim results from a Phase IIb/III trial of its ganetespib treatment for lung cancer. Synta is assessing the drug in combination with docetaxel, a leading chemotherapy. Comment! [Healthcare, On the Move]
Thursday, June 28, 2012, 9:05 AM Premarket gainers: SURG +41%. OREX +10%. AAV +5%.
Losers: ANTH -63%. SNTA -25%. VRTX -13%. BCS -12%. RBS -11%. FDO -7%. DB -5%. Comment! [On the Move]
Wednesday, June 27, 2012, 4:27 PM Synta Pharmaceuticals (SNTA) gets hit hard in post-session trading after announcing mixed interim results from its Phase 2b study of ganetespib, a treatment for advanced non-small cell lung cancer. The company says it plans to proceed to Phase 3. Shares -17% AH. Comment! [Healthcare, On the Move]
Monday, June 4, 2012, 1:29 PM BMO Capital adds to Synta Pharmaceuticals (SNTA +3%) updraft, upgrading it Outperform ahead of its full GALAXY data release and a more constructive view of ganetespib's potential for success. Ther firm also raises its price target to $10 from $5. Comment! [Healthcare, On the Move]
Monday, June 4, 2012, 11:29 AM Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug candidate, showed positive results as a treatment for oncologic indications, including a reduced rate of ocular toxicity. SNTA's primary research focus is on treatments for severe conditions such as cancer and chronic inflammatory diseases. Comment! [Healthcare, On the Move]
Monday, May 21, 2012, 4:19 PM Syntha Pharmaceuticals (SNTA +7.9%) gets a pop today after Jefferies initiated the shares with a Buy rating and a price target of $7. Comment! [Healthcare]
Tuesday, February 7, 2012, 5:25 PM Small biotechs are almost always highly speculative, so it's essential that any investor who seeks to venture into those murky waters start with informed research of the sort analyst Ohad Hammer provides in his overview of five biotechs to watch: EXEL, CLDX, SGEN, ARRY, SNTA. (h/t Mick Weinstein) Comment! [Healthcare, Quick Ideas]
Thursday, January 5, 2012, 5:09 PM Synta Pharmaceuticals (SNTA) announces a secondary offering for an undisclosed amount of shares. Jefferies is acting as sole book-running manager. Shares -11.5% AH. Comment! [Healthcare, On the Move]

Brennan Basnicki
$APOL $OCN $MON $SNTA on top of watch list for tomorrow
Jan 6, 11:06 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
$ONCY potential is huge. Reolysin can also be used for many other cancer types. Following: $CYCC $CYTK $ONCY $SNTA $SRPT $YMI
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/Q9LjsA Stocks for Nov 13th: $UBNT, $SNTA, $STRA, $BBY, $ZIOP, $WFT
11/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
New Post: Insider Weekends http://bit.ly/Mag8VF Buys: $OPK $SNTA $WSM $LPI $AIR || Sells: $STX $ENSG $MIDD $NOW $EGAS
7/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Big Wave Trading Portfolio Update And Top Current Holdings http://bit.ly/LEAhD2 SNTA FU MAGS VRNM BVSN PHMD AVD ANGI
6/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

TruffelPig
15% gain on my SNTA shares I bought yesterday :). Still holding.
6/29/12
Reply (5)

• !Report Abuse
View all 5 replies
tuliptown: am long as well. What does the HUGE volume down mean to you? Who were the weak hands leaving and who are buying? agree data was good.
7/1/12
• !Report Abuse
TruffelPig: I don't know - if the fold 'em I will hold :)
7/2/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
SNTA: I did read the data - they were actually pretty good; progression free time at least doubled, in some groups tripled
6/28/12
Reply (3)

• !Report Abuse
View all 3 replies
TruffelPig: Something similar happened to ECYT end of last year - the "expert" investors also sold and were WRONG.
6/28/12
• !Report Abuse
TruffelPig: As a biochemist I pressed the buy button today! Price target $10 in the next 12 month. Good story.
6/28/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
Buying op on SNTA - I got long finally. Good data and -27% - lol
6/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
SNTA - 72% Barchart technical buy signal - 12 new highs and up 49.68% in the past year 0 Relative strength Index 72.23%
6/8/12
Reply (1)

• !Report Abuse
View all 1 replies
TruffelPig: SNTA is simply a good company.
6/8/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/KW1sxj Earnings premarket $FLWS $ARG $ANR $ANSS $BCRX $CAH $CI $CNP, $EXXI $GM $LVLT $OWW $GOLD $VIAB $SNTA $HSH
5/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

TruffelPig
15% gain on my SNTA shares I bought yesterday :). Still holding.
6/29/12
Reply (5)

• !Report Abuse
View all 5 replies
tuliptown: am long as well. What does the HUGE volume down mean to you? Who were the weak hands leaving and who are buying? agree data was good.
7/1/12
• !Report Abuse
TruffelPig: I don't know - if the fold 'em I will hold :)
7/2/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
SNTA: I did read the data - they were actually pretty good; progression free time at least doubled, in some groups tripled
6/28/12
Reply (3)

• !Report Abuse
View all 3 replies
TruffelPig: Something similar happened to ECYT end of last year - the "expert" investors also sold and were WRONG.
6/28/12
• !Report Abuse
TruffelPig: As a biochemist I pressed the buy button today! Price target $10 in the next 12 month. Good story.
6/28/12
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
SNTA - 72% Barchart technical buy signal - 12 new highs and up 49.68% in the past year 0 Relative strength Index 72.23%
6/8/12
Reply (1)

• !Report Abuse
View all 1 replies
TruffelPig: SNTA is simply a good company.
6/8/12
• !Report Abuse
Add a reply...

140 characters

Todd Theman
Looking for an entry point into SNTA. Is $4 reasonable? Looking for a bump in advance of ASCO this summer.
4/20/12
Reply (1)

• !Report Abuse
View all 1 replies
PYRAMIDHUNT: An insider bought $5,000,000 of shares at $4.40 just a couple months ago.
4/28/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
Market potential for SNTA ganetespib is ridiculous. If it works in half the cancers they are studying, $10B+ potential.
12/9/11
Reply (8)

• !Report Abuse
View all 8 replies
1980XLS-2.0: Offer from GE, and XOM has already happened.
12/9/11
• !Report Abuse
The Scientist: I am a MD, PhD. I used to spend all my time in a molecular biology lab. Now I practice medicine.
12/10/11
• !Report Abuse
Add a reply...

140 characters

SNTA Synta Pharmaceuticals Corp.

SNTA

Synta Pharmaceuticals Corp.